Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”

PolyADP ribose polymerase inhibitors (PARPi) have transformed the treatment of ovarian cancer. Particularly in high-grade serous ovarian cancer (HGSOC), a disease characterized by homologous recombination deficiency (HRD), PARPi have had a rapid and profound impact on the disease course, as well as...

Descripción completa

Detalles Bibliográficos
Autores principales: Pejovic, Tanja, Fitch, Katherine, Mills, Gordon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2022
Materias:
Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255235/
https://www.ncbi.nlm.nih.gov/pubmed/35800377
http://dx.doi.org/10.20517/cdr.2021.138
_version_ 1784740882851823616
author Pejovic, Tanja
Fitch, Katherine
Mills, Gordon
author_facet Pejovic, Tanja
Fitch, Katherine
Mills, Gordon
author_sort Pejovic, Tanja
collection PubMed
description PolyADP ribose polymerase inhibitors (PARPi) have transformed the treatment of ovarian cancer. Particularly in high-grade serous ovarian cancer (HGSOC), a disease characterized by homologous recombination deficiency (HRD), PARPi have had a rapid and profound impact on the disease course, as well as biologic and biomarker definitions of HGSOC, thereby creating a paradigm shift in the approach to treatment. In this review, we discuss the role of PARPi in the maintenance treatment of HGSOC, its effect on platinum sensitivity, and cross-resistance between platinum and PARP inhibitors.
format Online
Article
Text
id pubmed-9255235
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher OAE Publishing Inc.
record_format MEDLINE/PubMed
spelling pubmed-92552352022-07-06 Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?” Pejovic, Tanja Fitch, Katherine Mills, Gordon Cancer Drug Resist Opinion PolyADP ribose polymerase inhibitors (PARPi) have transformed the treatment of ovarian cancer. Particularly in high-grade serous ovarian cancer (HGSOC), a disease characterized by homologous recombination deficiency (HRD), PARPi have had a rapid and profound impact on the disease course, as well as biologic and biomarker definitions of HGSOC, thereby creating a paradigm shift in the approach to treatment. In this review, we discuss the role of PARPi in the maintenance treatment of HGSOC, its effect on platinum sensitivity, and cross-resistance between platinum and PARP inhibitors. OAE Publishing Inc. 2022-06-01 /pmc/articles/PMC9255235/ /pubmed/35800377 http://dx.doi.org/10.20517/cdr.2021.138 Text en © The Author(s) 2022. https://creativecommons.org/licenses/by/4.0/© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Opinion
Pejovic, Tanja
Fitch, Katherine
Mills, Gordon
Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”
title Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”
title_full Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”
title_fullStr Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”
title_full_unstemmed Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”
title_short Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”
title_sort ovarian cancer recurrence: “is the definition of platinum resistance modified by parp inhibitors and other intervening treatments?”
topic Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255235/
https://www.ncbi.nlm.nih.gov/pubmed/35800377
http://dx.doi.org/10.20517/cdr.2021.138
work_keys_str_mv AT pejovictanja ovariancancerrecurrenceisthedefinitionofplatinumresistancemodifiedbyparpinhibitorsandotherinterveningtreatments
AT fitchkatherine ovariancancerrecurrenceisthedefinitionofplatinumresistancemodifiedbyparpinhibitorsandotherinterveningtreatments
AT millsgordon ovariancancerrecurrenceisthedefinitionofplatinumresistancemodifiedbyparpinhibitorsandotherinterveningtreatments

Ejemplares similares